Episode #1: Amylin Pharmaceuticals
From Approved · · 1 hr 46 min
This plays from the publisher's own server. We do not host a copy.
Description
Listen on Spotify (https://open.spotify.com/show/66IeBvvuoDma0ysf8c4I8Z)
Listen on Apple Podcasts (https://podcasts.apple.com/us/podcast/episode-1-amylin-pharmaceuticals/id1873356046?i=1000747377804)
Listen on YouTube (https://www.youtube.com/watch?v=cddzPaXBzqg)
TABLE OF CONTENTS
(00:00:00) - Introduction
(00:04:40) - $50 of Dried Lizard Venom
(00:29:17) - Fax of Death
(00:43:04) - Sleeping Beauty Awakens
(00:52:07) - Carl Icahn Sends a Letter
(01:09:19) - Endgame
(01:13:40) - Postmortem & Playbook
CREDITS
Co-hosted by Alex Kesin and Matthew Pech
Written, edited, and produced by Alex Kesin
Music: “Food” (https://www.youtube.com/watch?v=4PoCA4taNyg) by nerowski
* Special thanks to the team at NFX (https://www.nfx.com/) for the use of their recording studio.
SOURCES
Last updated: January 2026
I. PRIMARY DOCUMENTS
FDA Regulatory Documents
Symlin (pramlintide acetate) - NDA 21-332
* Approval Letter & Package (March 16, 2005) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_approv.PDF)
* Medical Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_medr.PDF)
* Statistical Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_statr.PDF)
* Clinical Pharmacology & Biopharmaceutics Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_biopharmr.PDF)
* Administrative Documents & Correspondence (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_admincorres.PDF)
Byetta (exenatide) - NDA 21-773
* Approval Letter & Package (April 28, 2005) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_approv.PDF)
* Medical Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_medr.PDF)
* Statistical Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_statr.PDF)
* Clinical Pharmacology & Biopharmaceutics Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_biopharmr.PDF)
* Administrative Documents & Correspondence (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_admincorres.PDF)
Bydureon (exenatide ER) - NDA 22-200
* Approval Letter (January 27, 2012) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000Approv.pdf)
* Other Action Letters (Complete Response) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000OtherActionLtrs.pdf)
* Summary Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumRedt.pdf)
* REMS (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000Rems.pdf)
* Administrative Correspondence (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000Admincorresedt.pdf)
SEC Filings & Financial Documents
* Amylin 2005 Results Press Release (Ex-99.1, 8-K) (https://www.sec.gov/Archives/edgar/data/881464/000110465906007417/a06-4671_1ex99d1.htm)
* Amylin 2007 Results Press Release (Ex-99.1) (https://www.sec.gov/Archives/edgar/data/881464/000110465908005085/a08-3824_1ex99d1.htm)
* Amylin 2011 Form 10-K (Net Product Sales) (https://www.sec.gov/Archives/edgar/data/881464/000119312512072788/d260205d10k.htm)
* Carl Icahn SEC Filing (Schedule 13D) (https://www.sec.gov/divisions/corpfin/cf-noaction/2009/icahnassociates032709-sec14-incoming.pdf)
Proxy Fight & Legal Documents
* Carl Icahn Letter to Amylin (April 15, 2009) (https://www.fiercebiotech.com/biotech/letter-from-carl-icahn-to-amylin-pharmaceutical)
* Amylin Response to Icahn (April 20, 2009) (https://www.fiercebiotech.com/biotech/amylin-letter-to-carl-icahn)
* Police Fund v. Bradbury (Amylin) Trial (May 4, 2009) (https://cvn.com/proceedings/police-fund-v-bradbury-amylin-trial-2009-05-04)
* Lilly Litigation Ruling (May 25, 2011) (https://investor.lilly.com/static-files/51a2a9a3-6b73-4e44-9f48-c22133624708)
II. ORAL HISTORY & INTERVIEWS
* Howard Greene Oral…